Developer docs
API playgroundTry for free, no card

Search company profiles

Nervosave Therapeutics

Full company profile

uuid000e3yp

Namestring
Nervosave Therapeutics
Legal namestring
SAS Nervosave Therapeutics
Websiteurl
nervosavetx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Nervosave Therapeutics is a privately held, preclinical French biotechnology company founded in October 2021 in Montpellier by Nicolas Tricaud (CEO/CSO, INSERM researcher and ERC laureate) and Cathy Beaumard (General Manager/Quality Officer). The company is developing a platform of local gene therapies targeting peripheral nerve diseases, with a primary focus on Charcot-Marie-Tooth disease type 1A (CMT1A) and broader demyelinating CMT diseases (CMT1 and CMT4), as well as non-genetic indications including diabetic peripheral neuropathy (DPN) and Guillain-Barré syndrome (GBS). Its core technology is an AAV9-based vector platform delivered via perineural injection, which achieves specific transduction of myelinating Schwann cells and is expected to provide very long-term therapeutic expression (>10 years) of biologics including peptides, mRNA, siRNA, and CRISPR-Cas9.

The pipeline comprises three programs: NVO-101 (AAV vector with siRNA, lead asset for CMT1A), NVO-301 (AAV gene therapy blocking Schwann cell demyelination for all demyelinating CMT diseases), and NVX-401 (peptide-based systemic therapy for DPN and GBS). Preclinical proof of concept has been demonstrated in CMT1A rat models (Gautier et al., 2021), with safety and molecular efficacy confirmed in non-human primates and translatability studies ongoing in sheep. The lead programs target a combined addressable population exceeding 2.5 million patients globally, including >68,000 CMT1A patients near disease onset, ~35 million DPN patients across the US/EU/China, and ~100,000 GBS patients in the US and EU.

Nervosave is pre-revenue and operates without disclosed equity funding; its inflows consist of non-dilutive grants (ERC award to the founder in 2012, MedVallée Boost Invest 2024) and regional incubation support from SATT AxLR, Region Occitanie, and BIC Montpellier. The team has been strengthened with the 2022 appointment of Sarah Abbas, MD, as CMO (clinical development of NVO-101) and the 2023 appointment of Sam Azoulay, MD, MBA, as consulting CEO. The company established an R&D laboratory at Sanofi BioPark Montpellier in February 2023. Its expected revenue model post-approval is one-time licensing or direct commercialization of ATMPs through specialized treatment centers, with potential platform out-licensing to larger pharmaceutical partners.

Short descriptiontext

Nervosave Therapeutics is a preclinical French biotech developing AAV9-based gene therapies delivered via perineural injection for peripheral nerve diseases, including Charcot-Marie-Tooth disease type 1A, broader demyelinating CMT, diabetic peripheral neuropathy, and Guillain-Barré syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontpellier, France
HQ citystring
Montpellier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy platform, peripheral nerve diseases, AAV9 gene therapy, charcot-marie-tooth treatment, rare disease therapeutics
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Gene Therapy Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Product Sales
TypeOne Time License
Description

As a clinical-stage biotech company developing gene therapies, Nervosave's primary expected revenue stream will come from commercialization of novel therapies for rare neurological diseases, likely through licensing agreements or direct commercialization upon regulatory approval.

nervosavetx.com
2Platform Licensing
TypeLicensing Royalties
Description

Potential for out-licensing platform technology or specific therapeutic candidates to larger pharmaceutical companies for development and commercialization.

nervosavetx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nervosave Therapeutics develops a platform of local gene therapies that slow, stop and reverse diseases involving peripheral nerves. Its lead candidate NVO-101 is a first-in-class AAV-based gene therapy for Charcot-Marie-Tooth disease type 1A, with NVO-301 extending the approach to broader demyelinating CMT diseases and NVX-401 providing a peptide-based treatment for diabetic peripheral neuropathy and Guillain-Barré syndrome. The platform uses AAV9 vectors delivered through perineural injection to specifically transduce myelinating Schwann cells and achieve long-term therapeutic expression.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AAV readily and specifically transduces target cells following local injection in nerves; vector biodistribution mostly restricted to injected nerves with very limited immune response
+3 more records
Product overview1 text field

Nervosave Therapeutics develops a platform of local gene therapies that target peripheral nerve diseases. The portfolio includes three therapeutic products: NVO-101 is an AAV-based gene therapy for Charcot-Marie-Tooth disease 1A (CMT1A), representing the first-in-class local therapy for this indication; NVO-301 is a next-generation AAV gene therapy addressing broader demyelinating CMT diseases (CMT1 and CMT4) by blocking Schwann cell demyelination; and NVX-401 is a peptide-based systemic treatment for Diabetic Peripheral Neuropathy and Guillain-Barré syndrome. The platform leverages AAV9 vectors with perineural injection delivery for localized, long-term therapeutic expression in peripheral nerves.

Product and service1 record
1NVO-101
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
3Business International Center (BIC) Montpellier
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
nervosavetx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established gene therapy company with AAV-based programs for neurological and rare diseases (e.g., Huntington's, ALS). Overlaps with Nervosave's AAV gene therapy approach to rare neurological disorders.

2Pharnext
TypeDirect peer
Description

Direct peer: French biotech focused on Charcot-Marie-Tooth disease 1A (PXT-3003), Nervosave's lead indication. Daniel Cohen, former Pharnext CEO, is listed as a Nervosave founding supporter, underlining direct strategic overlap.

TypeDirect peer
Description

Direct peer in CMT1A: antisense oligonucleotide approach targeting PMP22, the same pathophysiology Nervosave's NVO-101 addresses via AAV9-mediated silencing. Competes for the same rare-disease patient pool.

TypeBroad incumbent
Description

Clinical-stage AAV gene therapy company with CNS-focused pipeline; comparable on AAV delivery technology and neurological disease focus, though at a more advanced stage.

TypeBroad incumbent
Description

Approved gene therapy provider for neuromuscular diseases (e.g., DMD, Elevidys); comparable on rare neuromuscular disease gene therapy commercialization, though at a much larger scale and broader portfolio.

TypeEmerging player
Description

Emerging player in peripheral neuropathy gene therapy (e.g., Engensis for diabetic peripheral neuropathy), directly overlapping with Nervosave's NVX-401 indication in DPN.

TypeEmerging player
Description

Clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases; comparable as a peer AAV gene therapy developer targeting rare neurological indications.

TypeBroad incumbent
Description

Established AAV gene therapy platform company with multiple partnered programs (including neurological indications). Comparable as an AAV-based delivery platform peer, though operating at much broader scale.

TypeEmerging player
Description

Clinical-stage AAV gene therapy company for rare neurological diseases; comparable platform (AAV-based, rare CNS/PNS, central nervous system focus) and similar pipeline-development stage.

TypeEmerging player
Description

French non-profit gene therapy developer for rare diseases including neuromuscular indications. Nervosave's CMO Sarah Abbas previously led clinical programs at Genethon, making it a direct organizational and therapeutic-area peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nervosave Therapeutics

Gene Therapy Pharmaceuticalsnervosavetx.com

Nervosave Therapeutics is a preclinical French biotech developing AAV9-based gene therapies delivered via perineural injection for peripheral nerve diseases, including Charcot-Marie-Tooth disease type 1A, broader demyelinating CMT, diabetic peripheral neuropathy, and Guillain-Barré syndrome.

What Nervosave Therapeutics does

Nervosave Therapeutics is a privately held, preclinical French biotechnology company founded in October 2021 in Montpellier by Nicolas Tricaud (CEO/CSO, INSERM researcher and ERC laureate) and Cathy Beaumard (General Manager/Quality Officer). The company is developing a platform of local gene therapies targeting peripheral nerve diseases, with a primary focus on Charcot-Marie-Tooth disease type 1A (CMT1A) and broader demyelinating CMT diseases (CMT1 and CMT4), as well as non-genetic indications including diabetic peripheral neuropathy (DPN) and Guillain-Barré syndrome (GBS). Its core technology is an AAV9-based vector platform delivered via perineural injection, which achieves specific transduction of myelinating Schwann cells and is expected to provide very long-term therapeutic expression (>10 years) of biologics including peptides, mRNA, siRNA, and CRISPR-Cas9.

The pipeline comprises three programs: NVO-101 (AAV vector with siRNA, lead asset for CMT1A), NVO-301 (AAV gene therapy blocking Schwann cell demyelination for all demyelinating CMT diseases), and NVX-401 (peptide-based systemic therapy for DPN and GBS). Preclinical proof of concept has been demonstrated in CMT1A rat models (Gautier et al., 2021), with safety and molecular efficacy confirmed in non-human primates and translatability studies ongoing in sheep. The lead programs target a combined addressable population exceeding 2.5 million patients globally, including >68,000 CMT1A patients near disease onset, ~35 million DPN patients across the US/EU/China, and ~100,000 GBS patients in the US and EU.

Nervosave is pre-revenue and operates without disclosed equity funding; its inflows consist of non-dilutive grants (ERC award to the founder in 2012, MedVallée Boost Invest 2024) and regional incubation support from SATT AxLR, Region Occitanie, and BIC Montpellier. The team has been strengthened with the 2022 appointment of Sarah Abbas, MD, as CMO (clinical development of NVO-101) and the 2023 appointment of Sam Azoulay, MD, MBA, as consulting CEO. The company established an R&D laboratory at Sanofi BioPark Montpellier in February 2023. Its expected revenue model post-approval is one-time licensing or direct commercialization of ATMPs through specialized treatment centers, with potential platform out-licensing to larger pharmaceutical partners.

Nervosave Therapeutics firmographics

Firmographics
Name
Nervosave Therapeutics
Legal name
SAS Nervosave Therapeutics
Website
https://nervosavetx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Nervosave Therapeutics is a preclinical French biotech developing AAV9-based gene therapies delivered via perineural injection for peripheral nerve diseases, including Charcot-Marie-Tooth disease type 1A, broader demyelinating CMT, diabetic peripheral neuropathy, and Guillain-Barré syndrome.
Ownership category
akta.pro rank

Nervosave Therapeutics industry classification

Industry
Product category
Gene Therapy Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy platform
  • Peripheral nerve diseases
  • AAV9 gene therapy
  • Charcot-marie-tooth treatment
  • Rare disease therapeutics

Where Nervosave Therapeutics is headquartered

Location

Headquarters

HQ city
Montpellier
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Nervosave Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Gene Therapy Product Sales: As a clinical-stage biotech company developing gene therapies, Nervosave's primary expected revenue stream will come from commercialization of novel therapies for rare neurological diseases, likely through licensing agreements or direct commercialization upon regulatory approval.
  2. Platform Licensing: Potential for out-licensing platform technology or specific therapeutic candidates to larger pharmaceutical companies for development and commercialization.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Nervosave Therapeutics product offering

Product offering

Core offering

Nervosave Therapeutics develops a platform of local gene therapies that slow, stop and reverse diseases involving peripheral nerves. Its lead candidate NVO-101 is a first-in-class AAV-based gene therapy for Charcot-Marie-Tooth disease type 1A, with NVO-301 extending the approach to broader demyelinating CMT diseases and NVX-401 providing a peptide-based treatment for diabetic peripheral neuropathy and Guillain-Barré syndrome. The platform uses AAV9 vectors delivered through perineural injection to specifically transduce myelinating Schwann cells and achieve long-term therapeutic expression.

Product overview

Nervosave Therapeutics develops a platform of local gene therapies that target peripheral nerve diseases. The portfolio includes three therapeutic products: NVO-101 is an AAV-based gene therapy for Charcot-Marie-Tooth disease 1A (CMT1A), representing the first-in-class local therapy for this indication; NVO-301 is a next-generation AAV gene therapy addressing broader demyelinating CMT diseases (CMT1 and CMT4) by blocking Schwann cell demyelination; and NVX-401 is a peptide-based systemic treatment for Diabetic Peripheral Neuropathy and Guillain-Barré syndrome. The platform leverages AAV9 vectors with perineural injection delivery for localized, long-term therapeutic expression in peripheral nerves.

Differentiator

Problem solved

Functional benefit

Products and services

  • NVO-101

Quantifiable outcome

  • AAV readily and specifically transduces target cells following local injection in nerves; vector biodistribution mostly restricted to injected nerves with very limited immune response
  • +3 more outcomes

Companies that use Nervosave Therapeutics

Customer profile

Segments5 records

Ideal customer profiles2 records

Nervosave Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Nervosave Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Sanofi BioPark MontpelliercoreStrategic or Co-development Partner · 1 February 2023
  • SATT AxLRcoreStrategic or Co-development Partner · 1 November 2021
  • Business International Center (BIC) MontpelliercoreStrategic or Co-development Partner · 1 November 2021
  • INSERMcoreStrategic or Co-development Partner · 1 November 2021
  • Daniel Cohen (Pharnext)minorStrategic or Co-development Partner · 1 November 2021

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Nervosave Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • uniQure: Established gene therapy company with AAV-based programs for neurological and rare diseases (e.g., Huntington's, ALS). Overlaps with Nervosave's AAV gene therapy approach to rare neurological disorders.
  • Voyager Therapeutics: Clinical-stage AAV gene therapy company with CNS-focused pipeline; comparable on AAV delivery technology and neurological disease focus, though at a more advanced stage.
  • Sarepta Therapeutics: Approved gene therapy provider for neuromuscular diseases (e.g., DMD, Elevidys); comparable on rare neuromuscular disease gene therapy commercialization, though at a much larger scale and broader portfolio.
  • Regenxbio: Established AAV gene therapy platform company with multiple partnered programs (including neurological indications). Comparable as an AAV-based delivery platform peer, though operating at much broader scale.

Direct peers

  • Pharnext: Direct peer: French biotech focused on Charcot-Marie-Tooth disease 1A (PXT-3003), Nervosave's lead indication. Daniel Cohen, former Pharnext CEO, is listed as a Nervosave founding supporter, underlining direct strategic overlap.
  • Ionis Pharmaceuticals: Direct peer in CMT1A: antisense oligonucleotide approach targeting PMP22, the same pathophysiology Nervosave's NVO-101 addresses via AAV9-mediated silencing. Competes for the same rare-disease patient pool.

Emerging players

  • Helixmith: Emerging player in peripheral neuropathy gene therapy (e.g., Engensis for diabetic peripheral neuropathy), directly overlapping with Nervosave's NVX-401 indication in DPN.
  • Passage Bio: Clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases; comparable as a peer AAV gene therapy developer targeting rare neurological indications.
  • Taysha Gene Therapies: Clinical-stage AAV gene therapy company for rare neurological diseases; comparable platform (AAV-based, rare CNS/PNS, central nervous system focus) and similar pipeline-development stage.
  • Genethon: French non-profit gene therapy developer for rare diseases including neuromuscular indications. Nervosave's CMO Sarah Abbas previously led clinical programs at Genethon, making it a direct organizational and therapeutic-area peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Nervosave Therapeutics social profiles

Digital presence

Nervosave Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nervosave Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Nervosave Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nervosave Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nervosave Therapeutics

What does Nervosave Therapeutics do?

Nervosave Therapeutics develops a platform of local gene therapies that slow, stop and reverse diseases involving peripheral nerves. Its lead candidate NVO-101 is a first-in-class AAV-based gene therapy for Charcot-Marie-Tooth disease type 1A, with NVO-301 extending the approach to broader demyelinating CMT diseases and NVX-401 providing a peptide-based treatment for diabetic peripheral neuropathy and Guillain-Barré syndrome. The platform uses AAV9 vectors delivered through perineural injection to specifically transduce myelinating Schwann cells and achieve long-term therapeutic expression.

Is Nervosave Therapeutics a public or private company?

Nervosave Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nervosave Therapeutics founded?

Nervosave Therapeutics was founded in 2021. It employs 1 to 10 people.

Where is Nervosave Therapeutics based?

Nervosave Therapeutics is headquartered in Montpellier, France, in the Europe region.

How does Nervosave Therapeutics make money?

Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are platform Licensing.

Who are Nervosave Therapeutics's main competitors?

Broad incumbents on record are uniQure, Voyager Therapeutics, Sarepta Therapeutics and Regenxbio. Direct peers are Pharnext and Ionis Pharmaceuticals. Emerging players are Helixmith, Passage Bio, Taysha Gene Therapies and Genethon.

Does Nervosave Therapeutics have an API?

No public API is recorded for Nervosave Therapeutics.

What industry is Nervosave Therapeutics in?

Nervosave Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales